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The once heretical concept that a misfolded protein is the infectious agent responsible for prion
diseases is now widely accepted. Recent exciting research has led not only to the end of the skep-
ticism that proteins can transmit disease, but also to expanding the concept that transmissible
proteins might be at the root of some of the most prevalent human illnesses. At the same time,
the idea that biological information can be transmitted by propagation of protein (mis)folding raises
the possibility that heritable protein agents may be operating as epigenetic factors in normal bio-
logical functions and participating in evolutionary adaptation.The discovery that proteins can behave like infectious agents
to transmit disease is a significant milestone in biology. The
unorthodox prion hypothesis was proposed decades ago to
explain the surprising transmission mechanisms of a group of
rare diseases known as transmissible spongiform encephalopa-
thies (TSEs), or prion diseases (Griffith, 1967; Prusiner, 1982).
The prion hypothesis states that the infectious agent in TSEs is
composed exclusively of a misfolded form of the prion protein
(PrPSc), which replicates in infected individuals by transforming
the normal version of the prion protein (PrPC) into more of the
misfolded isoform (Prusiner, 1998). This hypothesis remained
controversial for decades, but recent studies have settled all
doubts by demonstrating that infectious material can be gener-
ated in vitro, in the absence of genetic material, by replication
of the protein misfolding process (Legname et al., 2004; Castilla
et al., 2005; Deleault et al., 2007; Wang et al., 2010). Despite the
obvious differences between prions and conventional infectious
micro-organisms (such as bacteria or viruses), prions exhibit the
typical characteristics of bona fide infectious agents, namely,
exponential multiplication in an appropriate host; transmission
between individuals by various routes, including food borne
and blood borne; titration by infectivity bioassays; resistance
to biological clearance mechanisms; penetration of biological
membrane barriers; ‘‘mutation’’ by structural changes forming
diverse strains; and transmission controlled by species barriers.
Although prions fulfill the Koch’s postulates for infectious agents,
it remains surprising that a single protein possesses the
complexity and flexibility required to act like living micro-organ-
isms that transmit disease.
Prion replication requires exposure to tiny quantities of PrPSc,
present in the infectious material, to trigger the autocatalytic
conversion of host PrPC to PrPSc. This process follows a crystal-
lization-like model in which the infectious particle (a small PrPSc
aggregate) acts as a nucleus to recruit monomeric PrPC into the
growing PrPSc polymer (Lansbury and Caughey, 1995). A key
step in prion replication is the breakage of large PrPSc aggre-968 Cell 149, May 25, 2012 ª2012 Elsevier Inc.gates into many smaller seeding-competent polymers that
amplify the prion replication process, resulting in the exponential
accumulation of PrPSc (Saborio et al., 2001). This seeding-nucle-
ation mechanism of prion propagation has been reproduced
in vitro to ‘‘cultivate’’ prions with infectious properties when inoc-
ulated into animals (Castilla et al., 2005; Deleault et al., 2007;
Wang et al., 2010). Additional research is needed to elucidate
the precise mechanisms and cellular factors required for prion
replication in vivo as well as the detailed structure of the infec-
tious folding of the prion protein (Soto, 2011).
The Prion Principle in Other Protein Misfolding
Disorders
The transformation of a natively folded protein into a misfolded,
toxic form that causes tissue damage and disease is not amech-
anism that is exclusive to prion diseases. Misfolded protein
aggregates are implicated in more than 20 human diseases,
collectively called protein misfolding disorders (PMDs), including
highly prevalent and insidious illnesses such as Alzheimer’s
disease, Parkinson’s disease, and type 2 diabetes (Soto, 2003;
Chiti and Dobson, 2006). Although the proteins implicated in
each of these pathologies and the clinical manifestations of the
diseases differ, the molecular mechanism of protein misfolding
is strikingly similar. Unfortunately, despite the extensive knowl-
edge about the molecular basis of these disorders, the factors
that trigger protein misfolding and initiate the pathology remain
unknown.
The protein misfolding processes in other PMDs share the
same replicationmechanism and result in the formation of similar
intermediates and end products as the PrPC-to-PrPSc conver-
sion in prion diseases. The protein conformational changes
associated with the pathogenesis of PMDs produce b sheet-
rich oligomers that are partially resistant to proteolysis and
have a high tendency to form amyloid-like aggregates (Soto,
2003; Chiti and Dobson, 2006). Interestingly, the available data
indicate that misfolding and aggregation processes in PMDs
Table 1. Potential Candidate Disease-Associated Transmissible Proteins
Disease Protein (Location) Experimental Transmission Natural Transmission Referencesa
Prion diseases PrPSc (extracellular) infectious in diverse animal
species by various routes
infectious in diverse
species by various
routes
(Prusiner, 1998; Aguzzi and Calella, 2009)
Alzheimer’s
disease
Ab (extracellular) induction of pathology in
transgenic mice by
intracerebral and
intraperitoneal inoculation
not shown (Kane et al., 2000; Meyer-Luehmann
et al., 2006; Eisele et al., 2010;
Morales et al., 2011)
Parkinson’s
disease
a-synuclein
(cytoplasmatic)
cell-to-cell and host-to-graft
spreading in animal models
and transmission by
intracerebral inoculation
host-to-graft
spreading
in humans
(Desplats et al., 2009; Luk et al., 2009;
Volpicelli-Daley et al., 2011;
Mougenot et al., 2012; Hansen et al.,
2011; Luk et al., 2012)
Huntington’s
disease
Huntingtin (nuclear) cell-to-cell spreading
in culture
not shown (Ren et al., 2009)
Tauopathies Tau (cytoplasmatic) cell-to-cell spreading in
culture and transmission
in transgenic mice by
intracerebral inoculation
not shown (Clavaguera et al., 2009; Frost et al., 2009;
Nonaka et al., 2010; Guo and Lee, 2011;
de Calignon et al., 2012; Liu et al., 2012)
Secondary
amyloidosis
Amyloid-A
(extracellular)
acceleration of pathology in
mice by various routes
of administration
possible
transmission to
captive cheetah
(Lundmark et al., 2002; Zhang et al., 2008)
Mouse senile
amyloidosis
Apolipoprotein A
(extracellular)
acceleration of pathology
in mice by various routes
of administration
transmission to
mice in the same
cage by feces
consumption
(Xing et al., 2001; Korenaga et al., 2006)
aThere are several more references that could have been cited, but due to space constraints, only the most relevant articles are listed.follow a seeding-nucleation mechanism (Harper and Lansbury,
1997; O’Nuallain et al., 2004; Soto et al., 2006). The process is
initiated by the slow interaction between protein monomers to
form a stable oligomeric nucleus (or seed) around which a faster
phase of polymeric elongation occurs. The limiting step in this
process is nuclei formation, and the rate of misfolding and
aggregation depends upon the number of seeds produced
(Harper and Lansbury, 1997). As described above, the key
element that makes PrPSc infectious is its ability to act as
a seed to induce the conversion of PrPC to PrPSc (Lansbury
and Caughey, 1995; Soto et al., 2006). In the same way as PrPSc,
extensive evidence indicates that oligomeric structures of the
proteins implicated in PMDs are able to seed accelerated
misfolding and aggregation of the natively folded monomeric
protein (O’Nuallain et al., 2004).
Given the striking similarities between the pathological
mechanisms of TSEs and other PMDs, a critical question is
whether other PMDs are transmissible and whether the
proteins implicated may also behave as infectious agents. In
this Perspective, we refer to the proteins able to propagate
biological information by the prion principle as ‘‘transmissible
proteins’’ to avoid the misunderstanding produced by calling
them prions. It is important to emphasize that the concept of
transmissible proteins does not necessarily imply that the
outcome of the transmission of protein misfolding should be
a disease, but as described in the sections below, transmis-
sible proteins could also be implicated in normal biological
processes or could even provide an evolutionary tool for envi-
ronmental adaptation.The putative transmissibility of PMDs has not been analyzed in
detail, but the lack of epidemiological data supporting disease
transmission is often used to rule out an infectious origin for
these diseases. However, it is likely that, without the fortuitous
transmission of sheep scrapie in 1937 (Cullie and Chelle, 1939)
or Gadjusek’s milestone discovery of kuru transmission by
cannibalism (Gajdusek et al., 1966), an infectious origin for
TSEs might have never been suspected. Indeed, epidemiolog-
ical studies of relatives and people in contact with Creutzfeldt-
Jakob disease (CJD) patients consistently produce negative
results. Epidemiological tracking of an infectious origin for these
diseases can be complicated by variable and extended time
between exposure to the infectious agent and the onset of
clinical symptoms, especially when this interval can be decades,
as is typical for human TSEs.
A series of recent studies has provided experimental evidence
for prion-like mechanisms of pathological transmission in
various common neurodegenerative diseases (Table 1). Alz-
heimer’s disease (AD) is associated with the misfolding and
aggregation of two proteins: amyloid-b (Ab) accumulation in
extracellular amyloid plaques and hyperphosphorylated tau,
which forms neurofibrillary tangles inside of neurons. To assess
the possibility that AD pathology might be transmissible by
a prion-like mechanism, transgenic mice expressing the human
amyloid protein were injected intracerebrally with diluted brain
homogenates derived from AD patients (Kane et al., 2000;
Meyer-Luehmann et al., 2006). The results clearly showed
accelerated Ab-deposition in the brain of inoculated animals.
Control experiments depleting the material from Ab aggregatesCell 149, May 25, 2012 ª2012 Elsevier Inc. 969
or inactivating their conformation did not produce acceleration of
the pathology, indicating that preformed Ab aggregates are
required to seed amyloid plaque deposition in vivo (Meyer-Lueh-
mann et al., 2006). Reminiscent to prions, seeding-competent Ab
aggregates are partially resistant to proteolysis and consist of
a continuum of various sizes, with the most efficient seeds being
smaller Ab oligomers (Langer et al., 2011). Oligomerization may
be enhanced by posttranslational modifications, such as pyro-
glutamylation, promoting the formation of the first seeds that
then propagate in a prion-like manner (Nussbaum et al., 2012).
However, unlike prion disease, which can be induced de novo
in animals that do not spontaneously develop the pathology,
the induction of Ab deposition observed in these studies only
represents an acceleration by a few months of the spontaneous
process that is set to occur by introduction of the mutant gene.
Recent experiments performed in transgenic animals expressing
low levels of wild-type human amyloid precursor protein find
that disease alterations can be induced in animals that, without
exposure to thismaterial, will never develop the pathology during
their entire life span (Morales et al., 2011; Rosen et al., 2012),
gettingmuch closer to the bona fide prion transmission observed
in TSEs. Another important step forward in the similarities
between Ab and prion transmission has been the demonstration
that AD brain abnormalities can be induced by intraperitoneal
inoculation of transgenic mice with Alzheimer’s brain extracts
(Eisele et al., 2010). This finding suggests that seeds acquired
by peripheral route of exposure may induce disease in the brain.
However, because the source of misfolded Ab used in these
experiments is sick brain homogenates, the relevance of these
findings for AD transmissibility is uncertain.
Various studies have been also performed to analyze the
transmission by seeding of tau aggregates, the other typical
feature of AD, which is also found in other neurodegenerative
diseases, collectively called tauopathies (e.g., fronto-temporal
dementia, chronic traumatic encephalopathy, etc). Intracerebral
injection of brain extract containing tau aggregates into trans-
genic mice expressing human wild-type tau that do not form
aggregates spontaneously induced the assembly of native tau
into misfolded aggregates in recipient mice (Clavaguera et al.,
2009). Interestingly, the pathology spreads over time beyond
the site of injection to anatomically connected neighboring brain
regions (Clavaguera et al., 2009). Unlike Ab and PrPSc, tau
aggregates are located in the cytoplasm, suggesting that, in
this case, protein misfolding is transmitted between cells. This
hypothesis is further supported by in vitro studies of cultured
cells in which extracellular tau aggregates were taken up and
induced the misfolding and aggregation of intracellular tau
(Frost et al., 2009; Nonaka et al., 2010; Guo and Lee, 2011).
These intracellular tau aggregates also spread among cells to
extend the pathology to the entire culture. Moreover, recent
studies using a transgenic mice overexpressing human mutant
tau only in a restricted area of the entorhinal cortex showed
that the pathology initiated in this region spread throughout
the brain even to areas without detectable human tau expression
(de Calignon et al., 2012; Liu et al., 2012). The progressive
accumulation of tau aggregates in these animals leads to
synaptic degeneration and later to axonal damage and neuronal
death.970 Cell 149, May 25, 2012 ª2012 Elsevier Inc.Several exciting neuropathological studies in Parkinson’s
disease (PD) patients additionally support the hypothesis that
prion-like spreading of the pathology is a common mechanism
in PMDs. PD is characterized by the accumulation of intracyto-
plasmic aggregates (termed Lewy bodies) made of a-synuclein
and primarily located in the substantia nigra. Autopsies of PD
patients who received grafts from healthy embryonic neurons
many years before showed that some transplanted neurons con-
tained a-synuclein aggregates (Li et al., 2008; Kordower et al.,
2008). Interestingly, studies designed to model these observa-
tions showed that transgenic mice developing a-synuclein inclu-
sions propagated the pathology to healthy neuronal grafts (Des-
plats et al., 2009; Hansen et al., 2011). This conclusion is
supported by in vitro experiments demonstrating the induction
of Lewy-body-like aggregates in neurons in culture by exposure
to a-synuclein aggregates (Luk et al., 2009; Nonaka et al., 2010;
Volpicelli-Daley et al., 2011). Moreover, coculture experiments
have shown transmission of misfolded a-synuclein aggregates
among cells in culture (Desplats et al., 2009). Finally, intra-
cerebral inoculation of transgenic mice expressing human
a-synuclein with extracts from old mice containing synuclein
aggregates or even with in vitro prepared synuclein aggregates
triggered an early onset of disease (motor alterations and accu-
mulation of protein aggregates), compared with uninoculated
mice that remained healthy (Mougenot et al., 2012; Luk et al.,
2012). These findings suggest that a-synuclein pathology is
spreading in the brain by a prion-like transmission process in
which intracellular aggregates gain access to the extracellular
space either by secretion or by damage of the host cell and
then get internalized into neighboring cells—most likely through
endocytosis—where they bind the normally folded, soluble
protein and template the misfolding process. It is also possible
that cell-to-cell transmission occurs through direct cellular
contact, involving nanotubes, or is mediated by exosomes or
microvesicles (Aguzzi and Rajendran, 2009). Similar findings
have been also reported with other misfolded proteins, such as
huntingtin, superoxide dismutase, and TDP-43, associated to
Huntington’s disease and amyothropic lateral sclerosis (Ren
et al., 2009; Mu¨nch et al., 2011; Grad et al., 2011; Furukawa
et al., 2011).
Transmission of protein misfolding may provide a mechanistic
explanation for the well-known but puzzling observation that
pathological changes in various neurodegenerative diseases
progress with time in a step-wise characteristic anatomical
pattern. Neuropathological studies by Braak et al. and various
other groups have shown that neurofibrillary tangles in AD and
Lewy bodies in PD initiate very early in the disease in a circum-
scribed area of the brain, and pathology progresses in a topo-
graphically predictable manner through anatomical connections
(Braak and Braak, 1991; Braak et al., 1996; Brundin et al., 2008).
The defined spatiotemporal progression of the lesions may well
be explained by spreading of misfolded proteins between cells
and by axonal transport between different brain regions to prop-
agate the pathology by transmission of protein misfolding.
The studies described above have come a longway in demon-
strating that spreading of protein misfolding may play a key role
in the pathogenesis and progression of many PMDs. Further-
more, these findings strongly suggest that at least some aspects
of the prion behavior, such as the molecule-to-molecule trans-
mission of protein misfolding and the cell-to-cell spreading of
the pathology, are indeed occurring in other PMDs. In this sense,
it is important to consider the likely possibility that, instead of
being exogenously acquired by infection, the first seeds might
be generated inside of the body by an unrelated biological
process, such as transcriptional/translational errors or tissue
injury (such as brain trauma or subclinical stroke). In the absence
of prion-like spreading, a small number of misfolded proteins
generated in this way would be short-lived and would not have
the long-lasting consequences that the prion transmission
process would produce. Another aspect that needs to be
considered is that misfolded aggregates composed of one
protein may interact and promote the aggregation of another
protein by a phenomenon known as cross-seeding. Evidence
for this phenomenon has been found for several PMDs by
studies in animal models, in vitro systems, and human epidemi-
ological analysis (see Morales et al., 2009 and references
therein). Thus, exposure to one misfolded protein may lead to
development of another PMD, further complicating epidemiolog-
ical tracking of a putative infectious origin of these diseases.
What Makes a Misfolded Protein Become an Infectious
Agent?
Despite the substantial advances over the past few years, the
central question remains: are other PMDs transmissible beyond
the experimental setting and the misfolded proteins prion-like
infectious agents? To answer this question, wemust understand
the requirements for a misfolded protein to act under ‘‘real-life
conditions’’ as an infectious agent. Based on the knowledge
accumulated from studies of mammalian prions, the following
properties are likely required (Figure 1).
(1) The transmissible protein must faithfully and efficiently self-
propagate. As discussed above, the seeding-nucleation mecha-
nism of protein misfolding and aggregation allows proteins to
replicate their folding characteristics. Notably, the most efficient
transmissible proteins might be those that form aggregates
stable enough to not spontaneously disassemble yet not so
stable to permit frequent fragmentation to multiply seeds.
(2) The transmissible protein must survive biological clearance
mechanisms. The net accumulation of misfolded aggregates
depends on a delicate equilibrium between new aggregate
formation and their elimination via several biological processes,
including metabolism, excretion, degradation, and correction of
protein misfolding. Indeed, several cellular pathways eliminate
misfolded, nonfunctional proteins, including the unfolded protein
response, the endoplasmic-reticulum-associated protein degra-
dation pathway, and autophagy. The high resistance of PrPSc to
proteases and extreme conditionsmay be key to the efficiency of
prions as infectious agents.
(3) The transmissible protein must reach the site of replication
and pathology. For PrPSc to produce TSEs, the agent must enter
the brain in quantities that are sufficient to trigger the slow but
progressive prion replication process. Moreover, when prions
are acquired by consumption of contaminated food, the trans-
missible protein must resist degradation in the digestive system
and penetrate the intestinal barrier. For misfolded proteins that
accumulate intracellularly, the transmissible protein must betransferred from one cell to another, or after cellular lysis, from
outside to inside the cell.
(4) The transmissible protein must trigger a phenotypic
change, which in the case of disease-associated proteins is
a toxic process resulting in cell damage, organ dysfunction,
and disease. Although accumulation of misfolded proteins is
clearly associated with cytotoxicity, we remain far from under-
standing the mechanism(s) by which misfolded aggregates
produce disease. Several pathways have been proposed,
including loss of the biological function of the natively folded
protein, formation of ionic channels, activation of receptor-medi-
ated signaling cascades, and sequestration of essential cellular
factors. For transmissible proteins not associated to a disease,
the self-propagating misfolding must result in a functional
change, which sometimes may contribute to evolutionary adap-
tation (see below).
The recent developments in the field have demonstrated that
misfolded proteins associated with various PMDs can initiate
the conversion of the normal form of the protein into the mis-
folded form and propagate these changes to neighboring cells
in experimental models. The exciting goal for future research is
to determine whether misfolded proteins implicated in PMDs
are infectious and transmit disease under natural conditions. In
other words, we need to carefully assess whether misfolded
proteins are transmitted between individuals and propagate
within communities as conventional infectious agents. Despite
the excitement generated by the recent findings, the strongest
evidence for transmissibility in PMDs other than TSEs was
generated by earlier studies in secondary reactive amyloidosis,
which is associated with amyloid-A protein aggregation (Lund-
mark et al., 2002), and mouse senile amyloidosis, which is
related to apolipoprotein AII aggregation (Xing et al., 2001)
(Table 1). In these diseases, even tiny quantities of misfolded
aggregates can be transmitted between individuals and can
cause disease by diverse routes, including blood transfusion
and oral administration. In the case of amyloid-A amyloidosis,
evidence also exists for natural transmission in captive cheetah
populations (Zhang et al., 2008).
Functional Transmissible Proteins: A New Biological
Paradigm?
Considering that several diseases might be transmissible by
propagation of protein misfolding, an intriguing question arises
of why transmissible proteins have not been eliminated during
evolution. One possible explanation is that these diseases are
postevolutionary disorders, as disease onset usually occurs
beyond the reproductive age of patients (Dobson, 2002). An
alternative possibility is that transmissibility of protein misfolding
may be a common process in biology that plays useful functions
in healthy cells—in other words, that many transmissible
proteins are constantly operating in organisms, silently providing
beneficial functions, and that the disease outcome produced in
some cases is just a degeneration of a normal biological process.
The view that the phenomenon of transmission of biological
information by propagation of protein misfolding is exclusive to
prion pathologies changed dramatically with the discovery of
proteins behaving like prions in yeasts and in other fungal organ-
isms (Table 2). In yeast, transmissible proteins do not behave likeCell 149, May 25, 2012 ª2012 Elsevier Inc. 971
Figure 1. Properties Required for Misfolded Aggregates to Behave as Transmissible Proteins
Based on the knowledge of the factors controlling prion transmission in vivo, it is likely that the following characteristics are needed for spreading of misfolded
proteins. (1) Efficient replication by the seeding-nucleation process. (2) Resistance to biological clearance, which in this figure is illustrated by proteasomal
degradation, chaperone refolding, and autophagy, though it is likely that other pathways might also be operating. (3) Ability to reach the target tissue and cellular
location, which is represented in the figure by cellular transport and spreading, and penetration across the intestinal and blood-brain barriers. The biological
barriers to be surmounted by the transmissible protein depend on the specific disease, subcellular location of the misfolded aggregates, and routes of exposure.
(4) Capability to transmit a biological change. For disease-associated misfolded proteins, the change is cellular damage, tissue dysfunction, and clinical disease,
and for functional transmissible proteins, the phenotypic change is the modulation of a biological activity or acquisition of a new function. In the figure, functional
changes are illustrated with the case of the Curli bacterial amyloid involved in biofilm formation (Chapman et al., 2002) and with the regulation of translational
termination by Sup35 in yeasts that may be implicated in evolutionary adaptation to environmental changes (True and Lindquist, 2000).
972 Cell 149, May 25, 2012 ª2012 Elsevier Inc.
Table 2. Functional Amyloids and Potential Candidates for Biological Transmissible Proteins
Protein (Organism) Protein Function
Changes Produced by
Misfolded State Transmissibility Referencesa
Sup35 (yeasts) translation
termination
reduced translational
fidelity; increased
survival in fluctuating
environments
transmitted from parent to
daughter cells during cell
division; synthetic prions
produced in vitro
(Wickner et al., 1995;
Derkatch et al., 1996;
Patino et al., 1996;
Tanaka et al., 2004)
Ure2 (yeasts) nitrogen
catabolism
indiscriminate utilization
of nitrogen sources
transmitted from parent to
daughter cells during
cell division; synthetic
prions produced in vitro
(Wickner, 1994;
Masison et al., 1997;
Brachmann et al., 2005)
Rnq1 (yeasts) unknown induction of other prions transmitted from parent
to daughter cells during
cell division
(Sondheimer and
Lindquist, 2000;
Patel and Liebman, 2007)
HET-S (P. anserina) heterokaryon
incompatibility
inhibits mycelia fusion transmitted from parent to
daughter cells during cell
division; synthetic prions
produced in vitro
(Coustou et al., 1997;
Maddelein et al., 2002)
CPEB (aplysia) translational
control of synapse-
specific mRNAs
maintains long-term
synapse facilitation
transmitted from parent to
daughter cells during cell
division in yeast; synthetic
prions produced in vitro
(Si et al., 2003, 2010;
Heinrich and
Lindquist, 2011)
MAVS (humans) antiviral signaling binding to the transcription
factor IRF3 and activation
of innate immunity
transmission in purified
mitochondrial cultures
(Hou et al., 2011)
Curli (bacteria) biofilm formation biofilm formation,
host invasion
not shown (Chapman et al., 2002)
Chaplins (bacteria) modulation of water
surface tension
aerial hyphae formation not shown (Claessen et al., 2003)
Microcin (bacteria) bacteriotoxin inhibit bacteriotoxic activity not shown (Bieler et al., 2005)
Chorion proteins
(insects and fish)
formation of eggshell protection of eggshell not shown (Iconomidou et al., 2000)
Spidroins and other
silk proteins (spiders)
silk formation structural component
of spider web
not shown (Kenney et al., 2002)
Various peptide
hormones (humans)
hormonal activity storage in pituitary
secretory granules
not shown (Maji et al., 2009)
Fragments of prostatic
acidic phosphatase
phosphatase activity capture and promote
HIV virion attachment to
target cells
not shown (Mu¨nch et al., 2007)
Pme17 (humans) pigment formation Scaffolding and
sequestration of toxic
products in melanin
synthesis
not shown (Fowler et al., 2006)
aThere are several more references that could have been cited, but due to space constraints, only the most relevant articles are listed.an infectious agent, killing their host cells to produce disease;
they are transmitted from parent cells to progeny, acting like
epigenetic factors to produce new metabolic phenotypes (Lind-
quist, 1997; Wickner et al., 2004). However, like mammalian
prions, yeast prions are proteins that have acquired an abnormal
conformation and propagate by inducing their normal protein
counterparts to adopt the same altered conformation. Thus, in
both cases, proteins act in a manner previously thought to be
unique to nucleic acids—in the mammalian case, as transmis-
sible agents of disease and, in yeasts, as heritable determinants
of phenotype.The discovery of transmissible proteins in yeast expanded
the prion concept and showed that transmission of protein
misfolding can also participate in normal biological processes
in addition to their established roles in disease pathology.
Currently, the number of proteins utilizing the prion mechanism
to perform their biological functions is unknown, but the regula-
tion of protein function by conversion to alternatively folded
forms without the need for genetic changes offers many advan-
tages that are likely to be conserved. A major goal of future
research will be to identify other transmissible proteins that
perform useful functions in healthy cells. Identification of newCell 149, May 25, 2012 ª2012 Elsevier Inc. 973
transmissible proteins is a challenging task, especially when the
result is not a dramatic disease, as in TSEs, or a weird genetic
property, as in yeast prions, but, rather, just a slight change in
the biological function of a particular protein. A genome-wide
study using bioinformatic techniques enabled the identification
of 200 prion candidates in S. cerevisiae, out of which at least
24 contain a prion-forming domain that is able to aggregate into
amyloid fibrils and confer prion characteristics to Sup35 (Alberti
et al., 2009). Strikingly, a recent study searching for the natural
presence of prions in wild strains of Saccharomyces found that
at least 33% of wild yeasts contain prion elements that
conferred diverse phenotypes that were frequently beneficial
under selective conditions (Halfmann et al., 2012).
In an interesting study, Kandel’s group reported prion-like
properties of a neuronal member of the cytoplasmic polyadeny-
lation element-binding protein (CPEB) family in Aplysia, which
regulates mRNA translation (Si et al., 2003; Si et al., 2010).
They hypothesize that CPEB conversion to a prion-like state in
stimulated synapses helps to maintain long-term synaptic
changes that are associated with memory storage. Interestingly,
unlike most yeast prions that propagate their phenotypic
changes by the loss of function of the normally folded protein,
it is the prion conformation of CPEB that is the active form. A
recent study shows that the yeast CPEB homolog in the absence
of any neuronal factors can stably adopt either active or inactive
states (Heinrich and Lindquist, 2011). Moreover, yeast CPEB can
adopt several distinct activity states, or ‘‘strains,’’ that can
remain stable for a long time (Heinrich and Lindquist, 2011).
Finally, purified recombinant CPEB aggregated into amyloid
fibrils can transform the endogenous CPEB into the functional
form in yeast. These findings suggest that CPEB employs a prion
mechanism to create stable, finely tuned self-perpetuating
biochemical memories.
The most recent addition to the functional prion arsenal was
reported by Hou and colleagues (Hou et al., 2011). The mito-
chondrial protein MAVS, which plays a critical role in antiviral
signaling, acquires conformational changes upon viral infection,
leading to the formation of large protein aggregates that propa-
gate in cultured cells to induce an efficient innate immune
response. Strikingly, recombinant MAVS protein can form
fibrillar aggregates in vitro and recruit endogenous MAVS into
the functional form in purified mitochondria (Hou et al., 2011).
The prion amplification cascade may provide a mechanistic
explanation for the high efficiency of this antiviral pathway, which
can be activated with less than 20 molecules of viral RNA (Zeng
et al., 2010). The utilization of the prion-like mechanism for this
critical signaling pathway is another elegant example of the
high potential of functional transmissible proteins in biology.
A common characteristic of all of the transmissible proteins
known so far is that the misfolded version forms b-sheet-rich
aggregates that resemble amyloid fibrils. Protein oligomeriza-
tion in b sheet structures is not only a typical characteristic of
prions, but also the key element that enables them to propa-
gate by a seeding mechanism. Therefore, one way to identify
new ‘‘functional transmissible proteins’’ is to search for proteins
that form b-sheet amyloid-like aggregates in their normal
cellular functioning. Functional amyloids have been described
in various organisms from bacteria to humans (Table 2). Acqui-974 Cell 149, May 25, 2012 ª2012 Elsevier Inc.sition of an amyloid structure has been shown to participate in
a variety of functions, including biofilm development, regulation
of cytotoxicity, modulation of water surface tension, formation
of spider webs, eggshell protection, enhancement of HIV viral
infection, modulation of melanin biosynthesis, and storage of
peptide hormones (Fowler et al., 2007). Although the proteins
involved in these processes form b-sheet-rich amyloid-like
aggregates following a seeding-nucleation model of polymeri-
zation, additional research is needed to determine whether
these proteins naturally propagate their phenotype using the
prion principle.
The notion that protein misfolding and aggregation into
amyloid structures is associated with a small family of proteins
has dramatically changed in recent years. The pioneering work
of Dobson and colleagues has demonstrated that many (if not
all) proteins can form b sheet intermolecular interactions to adopt
an amyloid-like conformation under appropriate conditions (Chiti
and Dobson, 2006). Even prototype globular and a-helical
proteins can form amyloid structures, arguing that amyloid is
the primordial conformation of proteins (Dobson, 2002). Strik-
ingly, the structures formed and the underlying mechanism of
misfolding and aggregation (following a seeding-nucleation
model) are similar to those associated to PMDs. These findings
suggest that any protein has the potential to form misfolded
aggregates under appropriate conditions, which then could
replicate by the prion principle. Taken together, these results
form the basis of a general biological principle whereby protein
function and activity might be regulated by folding changes
that can be rapidly propagated from protein to protein. An
exciting future research goal is, therefore, to determine whether
the prion phenomenon of propagation of biological information is
indeed a widespread process in biology.
A Role for Transmissible Proteins in Evolution
The rapid and autocatalytic transformation of a protein to an
alternate structure may also be used to adapt to challenging
environmental conditions. In this way, living organisms can
have the flexibility to change rapidly, providing a mechanism
for intragenerational evolution without the need for long-term
genetic changes. This evolutionary mechanism based on trans-
missible proteins can be used as a strategy for rapid adaptation
and survival of organisms facing new or short-term environ-
mental challenges, prior to more permanent adaptation by
natural selection of genetic modifications (Halfmann et al.,
2010). A possible example of this evolutionary mechanism can
be found in the Sup35 yeast prion (True and Lindquist, 2000).
When Sup35 is converted to the alternatively folded and aggre-
gated form, it allows the temporary translation of normally
untranslated DNA sequences. This mechanism enables very
rapid switches between distinct phenotypes, facilitating environ-
mental adaptation and the development of new evolutionary
traits (True and Lindquist, 2000). Interestingly, several other
yeast prions have been shown to modulate gene expression
(Halfmann et al., 2010). This effect may multiply the biological
and adaptive consequences of responses to environmental
changes that lead to the formation of the prion state. The selec-
tive enrichment of transmissible proteins (at least in yeasts)
among proteins that modulate genetic control suggests that
molecular switches based on self-propagating infectious
proteins may be very effective in producing biological diversity
upon which natural selection and evolution may occur.
Because transmissible proteins depend on the propagation
of changes in protein conformation, it is not surprising that
fluctuating environments trigger prion mechanisms. Indeed,
protein folding is highly responsive to changes in environmental
conditions such as temperature, pH, salinity, and metal ion
concentration. Thus, alterations in these parameters may lead
to protein misfolding and formation of oligomeric seeds with
the consequent rapid propagation of the misfolding event by
the prion principle. Another way by which the formation of mis-
folded transmissible proteins may be controlled by environ-
mental changes is through stimulation of cellular protein quality
control pathways. The emergence of diverse prions and
amyloids is tightly regulated by the cellular signaling pathways
involved in protein folding. A particularly important role in this
sense is played by molecular chaperones, which usually act to
prevent, correct, or eliminate misfolded proteins (Broadley and
Hartl, 2009). However, in some cases, molecular chaperones
may facilitate the propagation of protein misfolding. For
example, the Hsp104 chaperone enhances replication of various
yeast prions by facilitating fragmentation of large polymers and
multiplying the number of infectious nucleating seeds (Wegrzyn
et al., 2001).
Thus, environmental changes may directly or indirectly induce
protein misfolding events that rapidly propagate by the prion
mechanism, resulting in phenotypic changes that may enable
an organism to better adapt to new conditions. The phenotypic
changes can result from loss of the biological function of the
correctly folded protein or from the acquisition of new biological
functions after misfolding. Interestingly, both mammalian and
yeast prions appear in various forms, often called strains in
analogy to genetic strains of traditional infectious agents (Col-
linge and Clarke, 2007). These prion strains are slightly different
conformers of the infectious protein that can either replicate at
a different rate or produce a distinct phenotypic outcome.
From an evolutionary viewpoint, the possibility that one type of
environmental change may lead to a variety of phenotypic mani-
festations enhances the chances of beneficial evolutionary
adaptation. At present, the idea that propagation of protein mis-
folding contributes to evolution is mostly speculative, and more
research is needed to assess this intriguing possibility.ACKNOWLEDGMENTS
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